Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
68.50    0.00 (0.00%)
Bid:
68.00
Ask:
69.00
Spread: 1.00 (1.471%)
Market Cap: £311.75m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

New OPTIM Software and Hardware

4 Aug 2014 07:00

RNS Number : 0911O
Avacta Group PLC
04 August 2014
 



4 August 2014

Avacta Group plc

("Avacta" or the "Group")

 

 

New OPTIM Software and Hardware

Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for human and animal healthcare, announces that Avacta Analytical has completed the development of two new OPTIM variants. Alongside this, the Group has released upgraded OPTIM software, intended to widen the range of potential customers. 

OPTIM, Avacta Analytical's protein characterisation instrument, was launched during 2010 as OPTIM 1000 and was substantially redeveloped into the OPTIM2 system during 2013. Designed to reduce the time and cost of therapeutic protein development, the OPTIM instruments can provide multiple protein stability-indications at high speed using ultra-low sample volumes.

Avacta has completed the development of upgraded software for the OPTIM platform, expanding the capabilities available to end users. Two new variants to the core OPTIM platform, OPTIM 375 and OPTIM 445, which incorporate incremental measurement capabilities are now available. The Directors consider that these two new variants and the related upgraded software widen the appeal of OPTIM in its core drug development market by focusing on applications to characterise the viscosity of samples and the stability of membrane protein targets.

Alastair Smith, Avacta Group Chief Executive of Avacta said: "Now that OPTIM is becoming established as a valuable tool for protein stability characterisation, we are working hard to expand the range of applications and measurement types that the system can support in order to broaden the instrument's market appeal and drive consumable usage. The latest developments are in response to the market demand, which is growing worldwide, that we have identified for viscosity determination on small samples and for stability characterisation of membrane protein targets which are a challenging but important class of protein samples."

 

 

Enquiries:

 

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tim Sykes, Chief Financial Officer

Tel: +44 (0) 844 414 0452

www.avacta.com

Numis Securities Limited

Michael Meade / Freddie Barnfield - Nominated Adviser

James Black - Corporate Broking

Tel: +44 (0) 207 260 1000

www.numiscorp.com

Media Enquiries

Walbrook PR Ltd

Mike Wort / Anna Dunphy

Tel: +44 (0) 207 933 8780

avacta@walbrookpr.com

 

 

 

 

About Avacta Group plc - www.avacta.com

 

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through three divisions:

 

Avacta Analytical

www.avactaanalytical.com

 

High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development.

Avacta Animal Health

www.avactaanimalhealth.com

 

Veterinary diagnostics reference laboratory, diagnostic kits and newly launched in-clinic blood analyser, Sensipod.

Avacta Life Sciences

www.avactalifesciences.com

 

Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development.

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADMGGRKMZGDZM
Date   Source Headline
18th Apr 20117:00 amRNSInterim Results
12th Apr 201112:42 pmRNSIssue of Equity
29th Mar 20117:00 amRNSExclusive distribution agreement with DKSH Japan
28th Mar 20117:00 amRNSAdditional Listing
22nd Mar 201110:11 amRNSAdditional Listing
17th Mar 20117:00 amRNSDirectorate Change
4th Mar 20117:00 amRNSTrading Statement
23rd Feb 20117:00 amRNSRe Agreement
3rd Feb 20117:00 amRNSRe Agreement
3rd Feb 20117:00 amRNSIssue of Equity
27th Jan 20114:55 pmRNSHolding(s) in Company
27th Jan 20117:00 amRNSDirector/PDMR Shareholding
26th Jan 20117:00 amRNSIssue of Equity
25th Jan 201111:57 amRNSHolding(s) in Company
21st Jan 20113:47 pmRNSAGM Result and Placing
12th Jan 20117:00 amPRNPlacing, Issue of Equity and related party transaction
5th Jan 201111:59 amPRNExercise of Warrants
4th Jan 20116:28 pmPRNHolding(s) in Company
4th Jan 20117:00 amRNSProduct Sale
31st Dec 20109:57 amPRNHolding(s) in Company
30th Dec 20102:36 pmPRNHolding(s) in Company
25th Nov 20107:00 amRNSProduct Launch
15th Nov 20107:00 amPRNGrant of Options to Directors
3rd Nov 20107:00 amRNSFinal Results
27th Oct 20107:00 amRNSProduct Sale
27th Oct 20107:00 amRNSProduct Sale
26th Oct 20107:00 amPRNIssue of Equity
14th Oct 20107:00 amRNSRe Agreement
20th Sep 20107:00 amPRNLicensing Agreement
7th Sep 20105:08 pmPRNHolding(s) in Company
6th Sep 20107:00 amPRNDistribution Agreement
6th Aug 20109:55 amPRNDirector/PDMR Shareholding
29th Jul 20107:00 amPRNIssue of Equity
6th Jul 20107:00 amPRNIssue of Equity
1st Jun 20107:00 amPRNChange of Adviser
30th Apr 20107:00 amPRNHalf-yearly Report
8th Mar 20107:00 amRNSNotice of Results and Trading Update
3rd Mar 20107:00 amRNSAcquisition
22nd Feb 20102:42 pmRNSDirector/PDMR Shareholding
25th Jan 20107:00 amRNSResult of AGM
21st Dec 200910:35 amRNSIssue of Equity
26th Nov 20097:03 amRNSPreliminary Results
26th Nov 20097:00 amRNSIssue of Equity
4th Nov 20097:00 amPRNNotice of Results
21st Oct 20097:00 amPRNPlacing and Issue of Equity
6th Oct 20097:00 amRNSOptim - Second Order
28th Sep 20097:00 amPRNRe Agreement
16th Sep 20093:03 pmRNSHolding(s) in Company
11th Sep 20094:26 pmRNSHolding(s) in Company
11th Sep 20093:59 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.